Emyria Limited (ASX: EVS) Webcast Replay
7th December, 2022
Emyria Limited (ASX: EMD) is an award-winning, clinical-stage biotech backed by Andrew Forrest with a world-first cannabinoid drug development platform and one of the largest real-world data sets of clinical insights to support cannabinoid drug development.
As a part of our ‘The Insiders: Meet the CEOs’ series, CEO and MD Dr Michael Winlo, provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 7th December 2022 at 12pm (AEDT).
Join the next The Insider: Meet the CEOs webcast
FEATURED SPEAKER
Dr Michael Winlo
CEO & MD - Emyria Limited (ASX: EMD)
Emyria’s world-first EMD-RX platform delivers ultra-pure cannabinoids with high bioavailability to support multiple, global, over-the-counter and prescription registration opportunities. The company has the world’s largest real-world data set of clinical insights and evidence that is used to support its cannabinoid drug development programs. Emyria’s clinical trial EMD-RX5 and preclinical EMD-RX7 cannabidiol (CBD) formulations are partnership ready and demonstrate benefits over incumbent technologies, including Epidyolex – the world’s leading registered CBD medication. The company also has one of the world’s largest reported databases of MDMA compounds currently in development and its MDMA-inspired drug program is targeted towards conditions such as Parkinson’s, ADHD, PTSD, narcolepsy and others with major unmet needs.
